293 related articles for article (PubMed ID: 31711994)
1. Repurposing of drugs as STAT3 inhibitors for cancer therapy.
Thilakasiri PS; Dmello RS; Nero TL; Parker MW; Ernst M; Chand AL
Semin Cancer Biol; 2021 Jan; 68():31-46. PubMed ID: 31711994
[TBL] [Abstract][Full Text] [Related]
2. Repurposing drugs in oncology: From candidate selection to clinical adoption.
Pantziarka P; Verbaanderd C; Huys I; Bouche G; Meheus L
Semin Cancer Biol; 2021 Jan; 68():186-191. PubMed ID: 31982510
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics.
Kirtonia A; Gala K; Fernandes SG; Pandya G; Pandey AK; Sethi G; Khattar E; Garg M
Semin Cancer Biol; 2021 Jan; 68():258-278. PubMed ID: 32380233
[TBL] [Abstract][Full Text] [Related]
4. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.
Mottini C; Napolitano F; Li Z; Gao X; Cardone L
Semin Cancer Biol; 2021 Jan; 68():59-74. PubMed ID: 31562957
[TBL] [Abstract][Full Text] [Related]
5. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
6. Old drugs, new uses: Drug repurposing in hematological malignancies.
Kale VP; Habib H; Chitren R; Patel M; Pramanik KC; Jonnalagadda SC; Challagundla K; Pandey MK
Semin Cancer Biol; 2021 Jan; 68():242-248. PubMed ID: 32151704
[TBL] [Abstract][Full Text] [Related]
7. Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target.
Islam S; Wang S; Bowden N; Martin J; Head R
Br J Clin Pharmacol; 2022 Jan; 88(1):64-74. PubMed ID: 34192364
[TBL] [Abstract][Full Text] [Related]
8. Turning liabilities into opportunities: Off-target based drug repurposing in cancer.
Palve V; Liao Y; Remsing Rix LL; Rix U
Semin Cancer Biol; 2021 Jan; 68():209-229. PubMed ID: 32044472
[TBL] [Abstract][Full Text] [Related]
9. Targeting STAT3 in cancer and autoimmune diseases.
Gharibi T; Babaloo Z; Hosseini A; Abdollahpour-Alitappeh M; Hashemi V; Marofi F; Nejati K; Baradaran B
Eur J Pharmacol; 2020 Jul; 878():173107. PubMed ID: 32278856
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing for cancer therapy, easier said than done.
Gonzalez-Fierro A; Dueñas-González A
Semin Cancer Biol; 2021 Jan; 68():123-131. PubMed ID: 31877340
[TBL] [Abstract][Full Text] [Related]
11. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
[TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
13. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.
Shaw V; Srivastava S; Srivastava SK
Semin Cancer Biol; 2021 Jan; 68():75-83. PubMed ID: 31618686
[TBL] [Abstract][Full Text] [Related]
14. Role of STAT3 signaling pathway in breast cancer.
Ma JH; Qin L; Li X
Cell Commun Signal; 2020 Feb; 18(1):33. PubMed ID: 32111215
[TBL] [Abstract][Full Text] [Related]
15. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Beebe JD; Liu JY; Zhang JT
Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035
[TBL] [Abstract][Full Text] [Related]
16. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
Huang Q; Zhong Y; Dong H; Zheng Q; Shi S; Zhu K; Qu X; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2020 Feb; 187():111922. PubMed ID: 31810784
[TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer.
Wu MM; Zhang Z; Tong CWS; Yan VW; Cho WCS; To KKW
Life Sci; 2020 Dec; 262():118522. PubMed ID: 33011217
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
20. Drug rechanneling: A novel paradigm for cancer treatment.
Kaushik I; Ramachandran S; Prasad S; Srivastava SK
Semin Cancer Biol; 2021 Jan; 68():279-290. PubMed ID: 32437876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
